CG Oncology (CGON) Investor presentation summary

Mechanism of action and clinical rationale

• Selectively replicates in and lyses bladder cancer cells, triggering a chain reaction of tumor cell death.

• Amplifies anti-tumor immune response by activating T and B cells, inducing immunologic memory.

Clinical development and trial design

• Programs target high-risk and intermediate-risk NMIBC, including BCG-naïve, BCG-exposed, and BCG-unresponsive populations.

• Multiple phase 2/3 studies and expanded access programs address significant unmet needs in NMIBC.

Efficacy and safety outcomes

• Monotherapy in BOND-003 Cohort C achieved a 75.5% complete response rate, with 97.3% free from progression to MIBC at 24 months.

• Combination therapy in CORE-008 Cohort CX showed CR rates of 85.7% (ITT) and 92.3% (efficacy-evaluable), with no treatment-related progression or severe adverse events.

• No grade 3 or higher treatment-related adverse events, deaths, or discontinuations reported in key cohorts.